Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Gene therapeutic conversion from APOE4 to APOE3 to prevent Alzheimer’s disease

Objective

The major genetic risk factor for late-onset Alzheimer’s disease (AD) is the presence of the E4 allele of apolipoprotein E (APOE4). APOE is the primary lipid transporter in the brain, mainly expressed by astrocytes, microglia and neurons. There exist three APOE alleles in humans (E2, E3, E4). APOE4 increases the AD risk by 15-fold in homozygous and by 4-fold in heterozygous individuals. The APOE3 is not associated with increased risk and APOE2 is even associated with a reduced AD risk. Thus, new strategies to convert APOE4 into APOE3 represent a valid disease preventing treatment target for AD. Gene therapies are becoming more and more efficient and safe. To exploit this potential, we will develop a gene-therapy that converts APOE4 to APOE3 for the preventive treatment of AD.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EV
Net EU contribution
€ 150 000,00
Address
VENUSBERG-CAMPUS 1/99
53127 Bonn
Germany
Region
Nordrhein-Westfalen Köln Bonn, Kreisfreie Stadt
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)